Weekly Cisplatin-Based Chemoradiotherapy Improves RFS and OS, Although Not Statistically Significant, for Patients with Cervical Cancer and Intermediate Pathologic Risk Factors By Ogkologos - September 24, 2025 546 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NRG Oncology/GOG-263/KGOG1008 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Holiday Travel: 11 Things To Know Before Hitting The Road With... November 20, 2019 A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target... November 21, 2025 New ESMO Local and Locoregional Prostate Cancer Living Guideline v1.0 February 19, 2026 Adding Pirtobrutinib to Venetoclax-Rituximab Shows Significant Improvement in PFS Among Patients... August 6, 2026 Load more HOT NEWS Teen Created App To Help His Non-Verbal Sister And Others Like... Why haven’t we cured cancer? – That Cancer Conversation Colonoscopy after Positive FIT Test Cuts Risk of Colorectal Cancer Death ΝΕΥΡΟΕΝΔΟΚΡΙΝΕΙΣ ΟΓΚΟΙ (ΝΕΤS)
